Stock Analysis on Net
Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

Analysis of Liquidity Ratios
Quarterly Data

Beginner level

Liquidity Ratios (Summary)

Zoetis Inc., liquidity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Current ratio 2.82 3.47 2.77 2.63 4.39 4.17 4.05 3.60 4.06 4.38 4.27 3.85 2.80 2.01 1.96 3.03 3.24 3.20 2.84 2.15 2.08 2.11 2.27
Quick ratio 1.94 2.39 1.69 1.67 2.72 2.58 2.55 2.24 2.31 2.62 2.60 2.34 1.71 0.94 0.92 1.47 1.51 1.49 1.36 1.17 0.98 0.98 1.07
Cash ratio 1.52 1.85 1.13 1.07 1.74 1.66 1.66 1.39 1.39 1.61 1.65 1.43 1.13 0.40 0.36 0.65 0.63 0.63 0.58 0.65 0.36 0.35 0.41

Based on: 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Zoetis Inc.’s current ratio improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Zoetis Inc.’s quick ratio improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Zoetis Inc.’s cash ratio improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020.

Current Ratio

Zoetis Inc., current ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Current assets 6,757  6,285  4,772  4,748  4,618  4,484  4,379  4,399  4,076  4,239  4,267  4,217  4,894  3,584  3,383  3,390  3,364  3,328  3,307  3,830  3,450  3,316  3,110 
Current liabilities 2,400  1,811  1,721  1,806  1,052  1,075  1,082  1,223  1,003  967  1,000  1,094  1,746  1,784  1,730  1,117  1,039  1,039  1,163  1,781  1,658  1,572  1,370 
Liquidity Ratio
Current ratio1 2.82 3.47 2.77 2.63 4.39 4.17 4.05 3.60 4.06 4.38 4.27 3.85 2.80 2.01 1.96 3.03 3.24 3.20 2.84 2.15 2.08 2.11 2.27
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.70 1.57 1.43 1.44 1.54 1.68 1.58 1.62 1.42 1.58 1.66 2.26 2.69 2.94 2.91 4.02 1.56 1.50 1.48 1.54 1.82 2.30 2.17
AbbVie Inc. 0.95 0.86 3.14 3.18 1.15 0.89 1.04 0.98 1.20 0.80 1.20 1.28 1.45 1.38 1.76 1.65 1.79 1.81 1.56 1.50 2.03 1.50 1.39
Amgen Inc. 2.28 2.18 1.59 1.44 2.89 2.89 2.77 2.79 3.08 3.39 3.88 5.49 6.07 6.20 4.41 4.11 4.35 3.97 4.95 4.44 5.42 5.48 5.53
Bristol-Myers Squibb Co. 1.67 1.47 1.66 1.60 3.83 3.88 1.93 1.61 1.53 1.40 1.52 1.55 1.59 1.59 1.60 1.55 1.47 1.56 1.48 1.30 1.81 1.76 1.94
Eli Lilly & Co. 1.36 1.22 1.11 1.16 1.17 1.13 1.12 1.73 1.91 1.40 1.41 1.32 1.38 1.39 1.24 1.37 1.62 1.54 1.60 1.53 1.51 1.50 1.41
Gilead Sciences Inc. 3.25 2.33 3.04 3.10 2.96 3.76 3.62 3.38 3.45 3.00 2.84 2.74 3.68 3.37 2.59 2.22 1.93 1.76 1.77 2.50 2.77 2.03 2.70
Illumina Inc. 3.88 3.76 4.10 6.69 6.82 6.79 3.66 2.49 2.46 2.74 2.71 3.99 4.22 3.88 3.49 3.29 3.62 3.69 4.31 3.43 3.79 3.09 2.90
Johnson & Johnson 1.48 1.25 1.31 1.26 1.26 1.33 1.44 1.47 1.72 1.65 1.58 1.41 1.32 1.34 2.52 2.47 2.73 3.08 2.83 2.17 2.51 2.49 2.44
Merck & Co. Inc. 1.30 1.32 1.11 1.24 1.26 1.21 1.37 1.17 1.44 1.33 1.42 1.33 1.43 1.50 1.59 1.78 1.89 1.87 1.64 1.55 1.62 1.62 1.61
Pfizer Inc. 1.40 1.42 1.03 0.88 0.90 1.47 1.54 1.57 1.43 1.16 1.27 1.35 1.43 1.34 1.44 1.25 1.11 1.37 1.44 1.49 1.62 2.14 2.45
Regeneron Pharmaceuticals Inc. 3.89 2.12 4.21 3.67 4.03 3.88 4.58 4.47 4.04 3.62 3.59 3.82 3.63 3.75 2.80 2.56 3.64 3.37 3.41 3.59 3.64 3.80 4.31
Vertex Pharmaceuticals Inc. 3.72 3.72 3.54 3.61 3.44 3.74 3.78 3.43 3.71 3.67 3.68 3.28 3.28 3.49 3.82 2.31 2.08 2.33 2.54 2.78 3.63 3.46 4.49

Based on: 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

1 Q3 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 6,757 ÷ 2,400 = 2.82

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Zoetis Inc.’s current ratio improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.

Quick Ratio

Zoetis Inc., quick ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Cash and cash equivalents 3,654  3,353  1,951  1,934  1,815  1,755  1,728  1,602  1,286  1,558  1,654  1,564  1,981  705  629  727  651  658  675  1,154  592  544  559 
Short-term investments —  —  —  —  12  25  65  99  105  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Accounts receivable, less allowance for doubtful accounts 1,012  984  965  1,086  1,030  994  970  1,036  929  973  943  998  1,009  975  954  913  915  888  908  937  1,038  993  905 
Total quick assets 4,666  4,337  2,916  3,020  2,857  2,774  2,763  2,737  2,320  2,531  2,597  2,562  2,990  1,680  1,583  1,640  1,566  1,546  1,583  2,091  1,630  1,537  1,464 
 
Current liabilities 2,400  1,811  1,721  1,806  1,052  1,075  1,082  1,223  1,003  967  1,000  1,094  1,746  1,784  1,730  1,117  1,039  1,039  1,163  1,781  1,658  1,572  1,370 
Liquidity Ratio
Quick ratio1 1.94 2.39 1.69 1.67 2.72 2.58 2.55 2.24 2.31 2.62 2.60 2.34 1.71 0.94 0.92 1.47 1.51 1.49 1.36 1.17 0.98 0.98 1.07
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 1.01 0.93 0.83 0.88 0.93 0.98 0.94 1.03 1.00 0.94 1.04 1.67 2.02 2.13 2.01 3.31 0.94 0.92 0.88 1.04 1.10 1.60 1.45
AbbVie Inc. 0.68 0.58 2.88 2.91 0.92 0.64 0.78 0.78 0.95 0.55 0.90 0.89 1.11 0.98 1.24 1.14 1.42 1.41 1.25 1.21 1.57 1.12 1.10
Amgen Inc. 1.65 1.60 1.10 1.01 2.28 2.41 2.37 2.44 2.68 2.94 3.42 4.98 5.46 5.47 3.96 3.68 3.90 3.52 4.44 3.97 4.75 4.76 4.68
Bristol-Myers Squibb Co. 1.43 1.26 1.38 1.26 3.63 3.61 1.64 1.39 1.31 1.18 1.29 1.37 1.38 1.36 1.37 1.35 1.24 1.30 1.22 1.07 1.30 1.23 1.44
Eli Lilly & Co. 0.79 0.68 0.64 0.68 0.66 0.67 0.65 1.20 1.36 0.96 0.87 0.91 0.94 0.92 0.78 0.98 1.06 1.00 0.98 1.04 1.01 1.01 0.95
Gilead Sciences Inc. 2.93 2.09 2.78 2.86 2.74 3.41 3.32 3.15 3.16 2.70 2.60 2.52 3.39 3.01 2.19 1.78 1.57 1.39 1.33 2.07 2.33 1.56 2.17
Illumina Inc. 3.40 3.28 3.61 6.00 5.99 5.95 3.28 2.23 2.20 2.39 2.35 3.43 3.65 3.32 2.98 2.75 3.05 3.09 3.63 2.90 3.17 2.59 2.42
Johnson & Johnson 1.17 0.92 0.98 0.94 0.93 0.95 1.01 1.08 1.22 1.17 1.08 1.04 0.92 0.91 2.06 2.04 2.25 2.54 2.32 1.77 1.93 1.87 1.80
Merck & Co. Inc. 0.77 0.84 0.66 0.78 0.80 0.75 0.88 0.72 0.95 0.82 0.86 0.83 0.97 1.03 1.13 1.24 1.31 1.26 1.13 1.04 1.05 1.02 1.09
Pfizer Inc. 0.93 0.98 0.60 0.50 0.50 0.71 0.72 0.84 0.94 0.72 0.76 0.93 0.95 0.88 0.94 0.84 0.70 0.94 0.99 1.07 1.08 1.62 1.81
Regeneron Pharmaceuticals Inc. 3.02 1.61 3.38 2.81 3.14 2.99 3.66 3.50 3.10 2.80 2.82 2.98 2.94 3.02 2.34 2.13 3.18 2.94 2.95 3.10 3.18 3.32 3.88
Vertex Pharmaceuticals Inc. 3.46 3.47 3.27 3.33 3.20 3.51 3.54 3.19 3.46 3.41 3.39 2.94 2.92 3.06 3.30 2.06 1.81 2.02 2.19 2.41 3.12 2.97 4.17

Based on: 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

1 Q3 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 4,666 ÷ 2,400 = 1.94

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Zoetis Inc.’s quick ratio improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.

Cash Ratio

Zoetis Inc., cash ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Cash and cash equivalents 3,654  3,353  1,951  1,934  1,815  1,755  1,728  1,602  1,286  1,558  1,654  1,564  1,981  705  629  727  651  658  675  1,154  592  544  559 
Short-term investments —  —  —  —  12  25  65  99  105  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Total cash assets 3,654  3,353  1,951  1,934  1,827  1,780  1,793  1,701  1,391  1,558  1,654  1,564  1,981  705  629  727  651  658  675  1,154  592  544  559 
 
Current liabilities 2,400  1,811  1,721  1,806  1,052  1,075  1,082  1,223  1,003  967  1,000  1,094  1,746  1,784  1,730  1,117  1,039  1,039  1,163  1,781  1,658  1,572  1,370 
Liquidity Ratio
Cash ratio1 1.52 1.85 1.13 1.07 1.74 1.66 1.66 1.39 1.39 1.61 1.65 1.43 1.13 0.40 0.36 0.65 0.63 0.63 0.58 0.65 0.36 0.35 0.41
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.46 0.46 0.34 0.38 0.41 0.37 0.36 0.45 0.59 0.36 0.45 1.08 1.41 1.45 1.33 2.82 0.54 0.51 0.47 0.67 0.70 1.22 1.07
AbbVie Inc. 0.33 0.25 2.50 2.56 0.61 0.32 0.38 0.47 0.57 0.22 0.56 0.59 0.73 0.59 0.71 0.66 0.87 0.86 0.81 0.77 1.05 0.74 0.72
Amgen Inc. 1.24 1.09 0.68 0.69 1.94 2.05 2.07 2.17 2.41 2.62 3.07 4.62 5.05 5.02 3.65 3.40 3.60 3.23 4.08 3.62 4.34 4.35 4.28
Bristol-Myers Squibb Co. 1.03 0.92 0.95 0.84 3.10 3.02 0.99 0.83 0.70 0.62 0.70 0.71 0.75 0.72 0.72 0.72 0.62 0.59 0.57 0.53 0.76 0.74 0.99
Eli Lilly & Co. 0.30 0.20 0.14 0.21 0.15 0.20 0.19 0.68 0.83 0.53 0.41 0.55 0.55 0.48 0.34 0.55 0.51 0.47 0.41 0.54 0.52 0.51 0.50
Gilead Sciences Inc. 2.52 1.79 2.34 2.50 2.39 3.03 2.97 2.84 2.81 2.38 2.25 2.19 2.96 2.48 1.70 1.29 1.11 0.84 0.76 1.48 1.68 0.96 1.52
Illumina Inc. 2.98 2.93 3.16 5.13 5.11 5.18 2.91 1.95 1.95 2.06 2.01 2.88 3.07 2.78 2.47 2.21 2.44 2.45 2.79 2.27 2.47 2.08 1.92
Johnson & Johnson 0.79 0.52 0.54 0.54 0.51 0.49 0.53 0.63 0.71 0.66 0.56 0.60 0.51 0.45 1.57 1.59 1.74 1.98 1.80 1.38 1.48 1.39 1.31
Merck & Co. Inc. 0.36 0.50 0.32 0.47 0.39 0.35 0.47 0.40 0.55 0.42 0.43 0.46 0.58 0.64 0.77 0.83 0.84 0.79 0.74 0.70 0.69 0.65 0.76
Pfizer Inc. 0.64 0.70 0.31 0.26 0.25 0.40 0.39 0.59 0.59 0.42 0.42 0.66 0.60 0.53 0.59 0.57 0.41 0.65 0.68 0.79 0.74 1.25 1.37
Regeneron Pharmaceuticals Inc. 1.29 0.85 1.95 1.53 1.63 1.56 2.14 1.95 1.55 1.26 1.28 1.24 1.21 1.23 1.00 0.84 1.47 1.10 0.92 1.29 1.22 1.00 1.38
Vertex Pharmaceuticals Inc. 3.07 3.03 2.72 2.85 2.88 3.14 3.14 2.83 3.08 2.98 2.99 2.59 2.55 2.67 2.88 1.81 1.56 1.72 1.86 2.06 2.68 2.72 3.91

Based on: 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-14), 10-Q (filing date: 2018-11-01), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-16), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

1 Q3 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,654 ÷ 2,400 = 1.52

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Zoetis Inc.’s cash ratio improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020.